Compare UCTT & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UCTT | DAWN |
|---|---|---|
| Founded | 1991 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.2B |
| IPO Year | 2004 | 2021 |
| Metric | UCTT | DAWN |
|---|---|---|
| Price | $79.80 | $21.49 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $75.00 | $24.43 |
| AVG Volume (30 Days) | 911.6K | ★ 1.5M |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,734,500,000.00 | $158,182,000.00 |
| Revenue This Year | $19.18 | $55.03 |
| Revenue Next Year | $17.36 | $28.12 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 20.60 |
| 52 Week Low | $18.02 | $5.64 |
| 52 Week High | $79.58 | $21.50 |
| Indicator | UCTT | DAWN |
|---|---|---|
| Relative Strength Index (RSI) | 72.93 | 79.82 |
| Support Level | $23.56 | $10.30 |
| Resistance Level | N/A | $21.50 |
| Average True Range (ATR) | 3.70 | 0.03 |
| MACD | 1.09 | -0.31 |
| Stochastic Oscillator | 96.88 | 77.78 |
Ultra Clean Holdings Inc, through its subsidiaries, manufactures and supplies production tools, modules, and subsystems for the semiconductor capital equipment industry. The product includes precision robotic solutions, gas delivery systems, and a variety of industrial and automation production equipment products; subsystems include wafer cleaning subsystems, chemical delivery modules, top-plate assemblies, frame assemblies, and process modules. Its customer base includes firms in the semiconductor capital equipment industry, medical, energy, industrial, flat panel, and research equipment industries. It has two segments: Products and Services. Its principal markets are the Americas, Asia Pacific, and EMEA.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY301 is an antibody drug conjugate (ADC) that has shown antitumor activity in preclinical models.